MiMedx Group, Inc. (MDXG)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 1
Do Nothing: fundamentalScore is 2 (below the required floor of 3), and the strategy requires fundamentalScore ≥ 3 before any bullish long entry; the chart independently offers no tradable setup (price 3.20 below SMA20 4.10, SMA50 4.42 and SMA200 4.24 with ADX 37.66 rising and MACD -0.31 expanding negative; RSI 20.57 is bounce-only, and any pullback limit would also be countertrend since price < sma50 and macdLine < 0).
Company overview
MiMedx Group, Inc. develops and supplies allografts from placental tissue for various medical applications. Utilizing its patented PURION process, the company ensures the safety and efficacy of its products, which are primarily used in wound care, surgical recovery, and burn treatment. MiMedx operates mainly in the United States with its headquarters in Marietta, Georgia.
Fundamental
weakMiMedx faces weak fundamentals due to a significant revenue decline and covenant default despite a strong cash position.
MiMedx is a placental allograft and wound-care company whose 2025 profitability was erased by the January 2026 Medicare skin-substitute reimbursement overhaul: Wound revenue fell 71% in Q3 2026 and total revenue 45%, driving GAAP operating losses and negative operating cash flow over the first nine months. The balance sheet remains genuinely strong - $120.8 million of cash and zero debt at 30 September 2026, a 4.35 current ratio and no going-concern language in any filing - but a disclosed covenant event of default, a pending $300 million secured-debt-funded acquisition of Sanara MedTech and an FTC Second Request make the forward picture weak with elevated risk. Trailing valuation optics look cheap only because they rest on the pre-2026 cash-flow base; on normalized earnings there is little cushion.
Sentiment
fairSentiment is mixed with a recent licensing deal offsetting negative earnings and regulatory challenges.
The dominant near-term driver is the Q3 2026 earnings reset (announced, 2026-10-28) — net sales down 45% to $62.3M with wound care down 71% on the Medicare skin-substitute reimbursement reset and FY2026 guidance reset to $250-260M — partly offset by a same-day $25M patent license agreement (announced, market-scored +0.4), and the media sentiment delta is a determinate deterioration from a +0.36 bullish baseline (late-September AXIOFILL court-ruling coverage) to an essentially flat 14-day window at roughly -0.03. Moderate red-flag cap applied for materially conflicting catalysts — bearish earnings, a price-target cut to $7 and an FTC Second Request on the Sanara merger against the reception-positive licensing leg — with no severe flag fired.
Technical
very weakThe stock is in a strong downtrend with no bullish setup, as indicated by oversold technicals.
Chart score 1 — bearish/broken structure. Price 3.20 sits below SMA20 (4.10), SMA50 (4.42), SMA200 (4.24), EMA9 (3.63), EMA21 (3.97) and the 2026-11-04 daily VWAP (3.275), having fallen from 4.88 on 2026-03-02 and from 4.03 on 2026-10-22 (-34% over the last month, including -15.5% on 2026-11-02). ADX14 37.66 and rising from 20.62 on 2026-10-22 is a direction-agnostic strength reading attached to a falling price, i.e. a strong and strengthening downtrend, not a base. MACD is negative and expanding (line -0.31 below signal -0.21, histogram -0.10). RSI14 20.57 and Williams %R -96.13 are deeply oversold, so a reflex bounce toward 3.44-3.55 is plausible, but that is bounce-only and not a bullish trend structure. The technical read is valid and preserved; the trade is suppressed by the fundamental override (fundamentalScore 2 < 3).
You’re looking at 2026-11-05 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

